Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

AGM Statement

22 Aug 2024 07:00

RNS Number : 3151B
Calnex Solutions PLC
22 August 2024
 

22 August 2024

Calnex Solutions plc

 

("Calnex", the "Company" or the "Group")

 

AGM Statement

 

Calnex Solutions plc (AIM: CLX), a leading provider of test and measurement solutions for the global telecommunications and cloud computing markets, provides an update on operations and trading ahead of its Annual General Meeting ("AGM") taking place at 9am today.

 

Highlights

· Launch of major Paragon-Neo release on track for H2 FY25, focused on 800Gb/s synchronisation testing

· Successful launch in H1 FY25 of SNE-X with 400GbE to capitalise on customer demand across the cloud computing and data centre markets

· New channel partner network now operational

· Telecoms market has remained challenging, but the Board is encouraged by early successes of Calnex's new product releases and with continued tight cost control the Board anticipates the Company's performance in FY25 will be in line with market expectations

 

Operational update

The launch of Calnex's major Paragon-Neo release remains on track for H2 FY25, with good progress made across the project. The first pre-production unit is undergoing testing with the customer and initial feedback has been positive. This Paragon-Neo release is focused on the area of 800Gb/s synchronisation testing, the next generation of high-speed Ethernet, and the Company is encouraged by the level of customer enquiries to date.

 

In H1, Calnex successfully launched SNE-X with 400GbE interfaces to capitalise on customer demand across the cloud computing and data centre markets. The product is the first network emulator of its kind for AI infrastructure and other high-performance computing networks.

 

As previously announced, following the review of Calnex's sales channels and channel partner arrangements earlier this year, the Board took the decision to terminate its reseller agreement with Spirent and commenced discussions with new and existing channel partners to facilitate changes to strengthen the current arrangements. The Company is pleased to confirm that its new channel partner network is now operational, covering the Group's territories of North America, Europe, Middle East and Africa, as well as Asia-Pacific, including those which were previously covered by the Spirent relationship.

 

Following the successful transition of sales and channel partner arrangements, the Company is now seeking to establish direct supplier agreements with several of its key customers to enhance these relationships. The Board remains confident that the new multi-channel arrangement will be earnings enhancing.

 

Market outlook and trading

As anticipated, the telecoms market has remained challenging throughout the first four months of FY25. While activity levels across the sector are generally expected to stay at subdued levels for the remainder of the year, the fundamental need for the Company's testing solutions remains strong. The Board is encouraged by the early successes of Calnex's new product launches, which are expected to underpin the Company's return to growth in H2 FY25.

 

Calnex continues to maintain tight cost control measures and benefit from a healthy balance sheet and the Board anticipates that the Company's performance in FY25 will be in line with market expectations.

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cavendish Capital Markets Limited - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

 

Alma Strategic Communications

+ 44(0) 20 3405 0213

Caroline Forde, Joe Pederzolli, Emma Thompson

 

 

Overview of Calnex

 

Calnex Solutions designs, produces and markets test and measurement instrumentation and solutions for the telecoms and cloud computing industries. Calnex's portfolio enables R&D, pre-deployment and in-service testing for network technologies and networked applications, enabling its customers to validate the performance of the critical infrastructure associated with telecoms and cloud computing networks and the applications that run on it.

 

To date, Calnex has secured and delivered orders in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Meta.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland, Stevenage, England and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSEEFLFELSEIA
Date   Source Headline
4th May 20237:00 amRNSNotice of Results and Investor Presentation
14th Apr 20236:03 pmRNSPDMR Dealings
14th Apr 20233:24 pmRNSDirector Dealing
15th Mar 20231:15 pmRNSDirector Dealings
14th Mar 20234:00 pmRNSPDMR Dealings
7th Mar 20239:05 amRNSSecond Price Monitoring Extn
7th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSTrading Update
15th Feb 202310:59 amRNSPDMR Dealings
19th Jan 20239:56 amRNSPDMR Dealings
17th Jan 20239:56 amRNSDirector / PDMR Dealings
17th Jan 20239:52 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSBoard Changes
13th Jan 20234:00 pmRNSDirector/PDMR Dealing
13th Dec 20222:15 pmRNSDirector / PDMR Dealings
22nd Nov 20227:00 amRNSInterim Results
21st Nov 20225:43 pmRNSDirector / PDMR Dealings
27th Oct 20227:00 amRNSNotice of Results and Investor Presentation
14th Oct 20223:53 pmRNSDirector/PDMR Shareholding
12th Oct 20221:29 pmRNSDirector / PDMR Dealings
15th Sep 20227:30 amRNSDirector/PDMR Dealing
17th Aug 20225:26 pmRNSResult of AGM
17th Aug 20227:00 amRNSAGM Statement
15th Aug 202210:26 amRNSDirector / PDMR Dealings
26th Jul 20223:33 pmRNSDirector / PDMR Shareholding
18th Jul 20227:00 amRNSNotice of AGM
14th Jul 20225:49 pmRNSDirector/PDMR Dealings
8th Jul 20226:01 pmRNSDirector / PDMR dealings
15th Jun 20227:00 amRNSExercise of Options
14th Jun 20227:00 amRNSBoard Update
6th Jun 20221:30 pmRNSDirector Dealing
24th May 20227:00 amRNSFY22 Final Results
6th May 20227:00 amRNSNotice of Investor Presentation
26th Apr 20229:13 amRNSAward of Options
22nd Apr 202210:50 amRNSHolding(s) in Company
21st Apr 20223:37 pmRNSPDMR Dealing
21st Apr 20227:00 amRNSCalnex receives two Queen’s awards for Enterprise
12th Apr 20227:00 amRNSAcquisition of iTrinegy and Update on Trading
1st Mar 20227:00 amRNSTrading Update
25th Jan 202210:00 amRNSDirector Dealing
11th Jan 20227:00 amRNSBoard Appointments
29th Nov 20212:00 pmRNSPrice Monitoring Extension
26th Nov 20219:55 amRNSHolding(s) in Company
23rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20214:35 pmRNSPrice Monitoring Extension
23rd Nov 20212:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20212:00 pmRNSPrice Monitoring Extension
23rd Nov 20217:00 amRNSInterim Results
10th Nov 20217:00 amRNSNotice of Results and Investor Presentation
3rd Nov 202111:03 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.